Fethiann recently participated in the “Taiwan Traditional Chinese Medicine and Herbal Supplements Trade Mission to Singapore,” organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA). During the trade mission, Fethiann presented landmark achievements in native Taiwanese botanical research. The company’s proprietary active ingredient development technologies—FLC (Maqaw) and FMO (Michelia)—successfully attracted significant interest from Singaporean biotech experts and distributors.

Exclusive API Technology: Transforming Native Taiwanese Plants into Key Global Biomedical Raw Materials

Fethiann highlighted two major R&D breakthroughs during the event, demonstrating its profound capabilities in the development of Botanical New Drug APIs (Active Pharmaceutical Ingredients):

• FLC Maqaw Soothing Cream (Exclusive Taiwanese API): Fethiann successfully extracted high-purity FLC phytochemical active ingredients from Maqaw (Mountain Pepper), a plant native to Taiwan. Integrating indigenous wisdom with scientific validation, Fethiann has transformed this into a key ingredient for gout-related joint pain relief and repair, making the “Maqaw Soothing Cream” a unique offering in the market.
• FMO Michelia Relaxation Eye Patch (Exclusive API): The proprietary FMO Michelia phytochemical active ingredient was developed specifically to address modern eye fatigue. The “Michelia Relaxation Eye Patch” utilizes scientific data to support its stress-relief efficacy, showcasing Fethiann’s technical expertise in converting traditional florals into high-performance biomedical products.

Strengthening the “Taiwan Brand” through Scientific Validation

At the trade mission on March 24, the Fethiann team provided Singaporean industry representatives with a comprehensive overview of the FLC and FMO APIs—covering everything from origin traceability and ingredient stability to clinical application potential.

“Singapore is our primary gateway into the high-end Southeast Asian biomedical market,” stated Fethiann. “By showcasing these two exclusive Taiwanese ingredient technologies, we aim to prove that Taiwan can elevate unique local biological resources to international API standards. We provide more than just products; we offer world-leading botanical drug core technology”.

Strategic Expansion into Southeast Asia: Leading the Modernization of Botanical Drugs

The mission concluded with several technical exchange intentions and confirmed the strong demand for “scientifically validated botanical medicines” in Singapore. Fethiann will continue to invest in the R&D of Taiwan’s native species, leveraging its exclusive API technology to bring Taiwan’s biotech prowess to the global stage.

Inquire Now about Our API Collaboration Solutions

Contact Our R&D Team